MDRNA Aims to Market Cequent FAP Drug, File Three INDs by 2011
April 08, 2010
MDRNA Aims to Market Cequent FAP Drug, File Three INDs by 2011
"We believe [the FAP drug] is a product that the combined company could commercialize with a small specialty sales force [with] minimal sales and marketing infrastructure," MDRNA's President and CEO Michael French said this week.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- MDRNA Plans Reverse Stock Split to Acquire Cequent, Changes Name
July 22, 2010 / Gene Silencing News - MDRNA to Acquire Cequent in $46M Stock Deal
April 1, 2010 / Gene Silencing News - Management Shake-Ups Consistent in RNAi, microRNA Markets Over Two Years
July 15, 2010 / Gene Silencing News - Advances in microRNA Field Help Define 2009 While RNAi Advances Despite Setbacks
December 31, 2009 / Gene Silencing News - With Thermo Fisher Acquiring Life Tech, RNAi Reagent Space Consolidates Further
April 18, 2013 / Gene Silencing News